The PSA blood test now used to screen for prostate cancer may predict how aggressively the cancer will spread, according to a study published Thursday in the New England Journal of Medicine.
The widely used screening test for prostate cancer did not detect most tumors, according to a study published Thursday in the New England Journal of Medicine.
Scientists announced Tuesday that a drug already on the market appears to reduce men's overall risk of developing prostate cancer, but also carries several serious side effects and may increase the risk of developing an aggressive tumor.
Scientists have identified a gene that plays a key role in whether prostate cancer spreads to other parts of the body or remains in the gland, where it is much less likely to cause harm, a study published Wednesday said.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.